In cancers such as prostate cancer and liver cancer, the activation of the classic IL6 signaling pathway is generally accompanied by tumor progression, which can be reversed by inhibition of the IL6/JAK/STATS pathway [30, 31]. Here, IL6 is linked to prostate carcinoma.